Physician profile
Lauren Scheffy
NPI 1154349694
$5,472.83
in general payments reported to CMS, 2019-2025
47 companies · $770 in 2025
The $770 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,329 · 2022: $1,583 · 2023: $915 · 2024: $876 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,219 · Consulting Fee: $175 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.43 |
| Consulting Fee | $175.00 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,649.77 | 2021-2023 | |
| Amgen INC. | $973.52 | 2022-2025 | Evenity, Otezla, Repatha |
| Genentech USA, INC. | $365.30 | 2021-2023 | Tecentriq, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $238.42 | 2022-2023 | Calquence, Imfinzi, Tagrisso |
| Lundbeck LLC | $160.65 | 2023-2025 | Rexulti, Vyepti |
| Merck Sharp & Dohme LLC | $154.75 | 2021-2023 | Lynparza, Keytruda |
| Janssen Biotech, INC. | $146.21 | 2022-2023 | Darzalex, Imbruvica, Tecvayli |
| Incyte Corporation | $140.29 | 2021-2023 | Jakafi |
| Coherus Oncology, INC. | $123.77 | 2021-2024 | |
| Pfizer INC. | $107.02 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $92.75 | 2023 | Imbruvica |
| Ardelyx, INC. | $89.78 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $86.18 | 2022-2023 | |
| Axsome Therapeutics, INC. | $81.92 | 2025 | Auvelity |
| Beigene USA, INC. | $79.40 | 2021-2023 | Brukinsa |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $73.87 | 2022-2024 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $64.14 | 2022-2023 | Enhertu |
| Antares Pharma, INC. | $55.32 | 2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $51.24 | 2021-2022 | |
| Itamar Medical INC | $49.33 | 2024 | Watchpatone |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.08 | 2025 | Caplyta |
| Taiho Oncology, INC. | $44.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.96 | 2022 | |
| Genzyme Corporation | $36.16 | 2021-2022 | |
| Astellas Pharma US INC | $36.01 | 2022 | |
| Exact Sciences Corporation | $32.29 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $31.46 | 2022 | |
| Dendreon Pharmaceuticals LLC | $31.41 | 2021 | |
| Recor Medical INC | $30.01 | 2025 | Paradise Ultrasound Renal Denervation System |
| Eisai INC. | $28.87 | 2022 | |
| Seagen INC. | $28.04 | 2023 | Adcetris |
| Welch Allyn | $24.97 | 2021 | |
| Adc Therapeutics America, INC. | $23.08 | 2023 | |
| Idorsia Pharmaceuticals US INC | $22.62 | 2024 | Quviviq |
| Cvrx, INC. | $22.60 | 2024 | Barostim Neo System |
| Morphosys, US INC. | $22.42 | 2023 | Monjuvi |
| Phathom Pharmaceuticals, INC. | $20.35 | 2025 | Voquezna |
| Celgene Corporation | $18.74 | 2023 | Pomalyst |
| Mylan Institutional INC. | $17.92 | 2023 | Fulphila, Ogivri |
| Otsuka America Pharmaceutical, INC. | $17.30 | 2023 | Nuedexta |
| Pharmacosmos Therapeutics INC. | $17.02 | 2023 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2023 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $16.25 | 2023 | Onivyde, Somatuline Depot |
| Novo Nordisk INC | $16.10 | 2024 | Ozempic, Rybelsus |
| Jazz Pharmaceuticals INC. | $15.28 | 2021 | |
| G1 Therapeutics, INC. | $14.63 | 2023 | Cosela |
| Abbvie INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Scheffy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.